Navigation Links
Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2013 Financial Results
Date:5/2/2013

his new treatment option available to patients in additional parts of the world."

APD811 

  • Initiated dosing of an additional cohort in a Phase 1 multiple dose clinical trial of APD811, an oral drug candidate that targets the prostacyclin (IP) receptor for the potential treatment of pulmonary arterial hypertension (PAH). This randomized, double-blind and placebo-controlled trial is designed to evaluate the safety, tolerability and pharmacokinetics of multiple-ascending doses of APD811 and to optimize the dosing regimen prior to potentially initiating a Phase 2 clinical trial.
  • APD334

  • Initiated dosing in a Phase 1 clinical trial of APD334, an oral drug candidate that targets the sphingosine 1-phosphate subtype 1 (S1P1) receptor for the potential treatment of various autoimmune diseases. This randomized, double-blind and placebo-controlled Phase 1 trial is designed to evaluate the safety, tolerability and pharmacokinetics of single-ascending doses of APD334.
  • "We are leveraging our validated research and development capabilities to continue to build and advance our pipeline of innovative drug candidates," said William R. Shanahan , M.D., Arena's Senior Vice President and Chief Medical Officer. "With APD811 and APD334, we look forward to potentially expanding the options available to patients and physicians for the treatment of PAH and certain autoimmune diseases, such as multiple sclerosis, rheumatoid arthritis and psoriasis."

    First Quarter 2013 Financial Results Arena recognized revenues totaling $2.4 million in the first quarter of 2013, compared to $2.2 million in the first quarter of 2012. The revenue recognized in 2013 includes a $500,000 milestone payment earned from Eisai upon filing the BELVIQ MAA in Mexico.

    Research and development expenses in the first quarter of 2013 decreased to $14.0 million, compared to $14.5 million in the f
    '/>"/>

    SOURCE Arena Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Arena Pharmaceuticals Announces First Quarter 2012 Financial Results and Recent Developments
    2. Arena Pharmaceuticals Announces Proposed Public Offering of Common Stock
    3. Arena Pharmaceuticals Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
    4. Aperture Health, Inc., Targeting the Strong Growth in the Long Term Disease Management arena
    5. Arena Pharmaceuticals Promotes Craig M. Audet to Executive Officer as Senior Vice President, Operations and Head of Global Regulatory Affairs
    6. Arena Pharmaceuticals to Present at the Seventh Annual JMP Securities Healthcare Conference
    7. Arena Pharmaceuticals Files Marketing Authorization Application in Switzerland for Lorcaserin as a Treatment for Weight Control
    8. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Thursday, August 9
    9. Arena Pharmaceuticals Announces Second Quarter 2012 Financial Results and Recent Developments
    10. Arena Pharmaceuticals to Present at Upcoming Investor Conferences
    11. Arena Pharmaceuticals to Present at the UBS Global Life Sciences Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/17/2014)... , Dec. 17, 2014 With advancements ... the MRI market is seeing new growth, according ... MRI scans account for the majority of market ... resolution of images, which are creating opportunities for more ... market is growing at a rate of 4%, ...
    (Date:12/17/2014)... 17, 2014  ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE ... Trademark Office (USPTO) has issued a key patent ... immunotherapeutic vaccine targeting six tumor antigens that are ... Patent No. 8,871,211, which issued October 28, 2014, ... a dendritic cell composition comprising peptide epitopes of ...
    (Date:12/17/2014)... KENNESAW, Ga. and RALEIGH, ... Clinical Trial Marketing Communications, LLC (CTMC), and Integrated ... in patient recruitment and retention for clinical trials ... called Integrated Clinical Trial Marketing Services (i-CTMS). i-CTMS ... and retention services to pharmaceutical, biotechnology and medical ...
    Breaking Medicine Technology:Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 3
    ... Inc. announced today that it has reached agreement with ... to incorporate its glucose sensor into Luminous, automated blood ... enable clinicians to control hyperglycemia in critical care patients ... use a sensing technology based on near-infrared spectrometry. ...
    ... , Four Companies Required to Stop Making and ... Md., Oct. 13 The U.S. Food and Drug ... marketing unapproved codeine sulfate tablets. These drugs are opioid ... treat pain. , (Logo: ...
    Cached Medicine Technology:Luminous Medical, Inc. Secures Exclusive Rights to Glucose Sensor for Its Automated Glucose Monitor 2FDA Acts to Halt Marketing of Unapproved Codeine Sulfate Tablets 2FDA Acts to Halt Marketing of Unapproved Codeine Sulfate Tablets 3
    (Date:12/20/2014)... AZ (PRWEB) December 20, 2014 Parker ... professional technicians with years of experience in contractor services ... dedicated contractor services for the homeowners of Arizona. Parker ... team a professional contractor technicians that make customer service ... 1974 in Phoenix Arizona and started with one service ...
    (Date:12/19/2014)... Sweetdressy.com , a leading wedding dress ... selection of cheap prom dresses for ladies worldwide. The ... world and clients can buy these dresses at the ... feature cool cuts and delicate craftsmanship, and most of ... market. Discount shipping costs are available for all of ...
    (Date:12/19/2014)... Silver Dollar City is picking up ... the first time ever, Silver Dollar City has a title ... 2015, listing the park’s wood coaster Outlaw Run as the ... announced this week, Silver Dollar City is named in CNN ... USA Today’s 10Best awards for “Best Public Lights Display,” and ...
    (Date:12/19/2014)... An evening dress is perfect for any ... Discount-Dress.com, a distinguished dresses retailer, has unveiled its new selection ... this great shopping platform. Customers can view more ... work, Discount-Dress.com has been accepted and praised by customers for ... shopping stage for clients. In order to expand its market ...
    (Date:12/19/2014)... Dec. 19, 2014 (HealthDay News) -- The intestinal bacteria ... and ulcerative colitis, may be inherited, researchers report. ... Medicine , could help in efforts to prevent the ... or colitis, the study authors added. "The intestinal ... young age can have a big impact on your ...
    Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Reaching A Milestone By Providing 40 Years Of Dedicated Contractor Services For Homeowners Of Arizona 2Health News:Parker & Sons Announces Reaching A Milestone By Providing 40 Years Of Dedicated Contractor Services For Homeowners Of Arizona 3Health News:Cheap Prom Dresses Online Now at Sweetdressy.com 2Health News:Silver Dollar City Nets New Titles: Guinness Book of World Records, Plus CNN Travel, USA Today & Fodor’s Top Places for Christmas Lights 2Health News:Attractive Evening Dresses Announced by Discount-Dress.com 2Health News:Crohn's, Colitis May Have Genetic Underpinnings, Study Finds 2
    ... CUPERTINO, Calif., Feb. 29 DURECT Corporation,(Nasdaq: ... and Chief,Executive Officer, will be presenting at the ... Financial Group on Tuesday,March 4, 2008 at 2:45 ... the W,Hotel, 541 Lexington Avenue, New York City., ...
    ... Feb. 29 TITAN Technology Partners, a,global provider ... the,fastest growing technology company in North Carolina in ... recognized health system,has signed a multi-year agreement to ... Financial and Human Capital Management,applications throughout the organization ...
    ... music industry,veteran and TV personality, is coming to ... about type 2 diabetes and its connection to,cardiovascular ... Heart,Association to speak on behalf of The Heart ... with type 2 diabetes manage the disease and,reduce ...
    ... Genoptix, Inc.,(Nasdaq: GXDX ), today announced the pricing ... certain existing stockholders to,the public at the price of ... from the sale. The offer is expected to close ... through an underwriting syndicate led by,Lehman Brothers, Inc. acting ...
    ... Feb. 29 Finesse Solutions, LLC and,Applikon ... the,TruConnect(TM) gateway, a migration device designed to ... ADI 1030 Controllers, and the Finesse,TruLogic(TM) Controller, ... control.), TruConnect(TM) gateways harmonize an installed ...
    ... Southwestern Medical Center have determined that the level, or saturation, ... with sickle cell anemia who are at an increased risk ... also found that a published method used to predict severe ... Stroke is a serious but increasingly preventable complication of sickle ...
    Cached Medicine News:Health News:Valley Baptist Health System Leveraging TITAN Technology Partners Hosting and Managed Services 2Health News:Randy Jackson and the American Heart Association Educate Cincinnati Area Residents about the Connection between Type 2 Diabetes and Cardiovascular Disease 2Health News:Randy Jackson and the American Heart Association Educate Cincinnati Area Residents about the Connection between Type 2 Diabetes and Cardiovascular Disease 3Health News:Genoptix Announces Pricing of Secondary Public Offering 2Health News:Applikon and Finesse Solutions Introduce TruConnect(TM) 2Health News:UT Southwestern researchers investigate predictors for sickle-cell-anemia complications 2
    ... Every Bard® Biopsy Instrument and Needle ... one important goal: a large quality, reliable ... exceptional performance, featuring ultra-sharp tips and polished ... broad selection of biopsy systems and needle ...
    ... Used to obtain multiple core biopsies ... biopsy needle is designed to fit ... micro-sharpening process that produces an ultrasharp ... histological cores. Uni-Cor™ has an etched ...
    ... offers a customized approach to performing ... associated with current stranded products as ... seed and spacer implant techniques.SourceLink™ Connectors ... quantity and seed activity level (in ...
    ... is designed to bring efficiency and quality ... combines the superior technology of fluorescent flow ... Continuous sampling or batch processing are ... sample processing in high volume laboratories. ...
    Medicine Products: